Shares of CHYM are trading around $34.55, up approximately 9% over the trailing 30 days and near their recent 52-week high. This advance builds on a sharp August rally, when the stock climbed roughly 44% after the company reported results that comfortably exceeded expectations. Since the start of 2026, CHYM has gained more than 30%, outperforming the broader financial technology landscape.
The move marks a notable shift in sentiment. After pricing its initial public offering at $27 in June 2025 and closing its first trading day around $37, the stock later slid below its IPO price amid concerns about slowing growth. The August earnings report reframed the narrative, and Chime's market capitalization has since returned to the range of roughly $12.8 billion reported in recent coverage. I checked comparable names using Tickeron’s AI Screener to see how CHYM stacks up against peers.
Chime Financial is a San Francisco-based financial technology company, not a bank. Founded in 2012 and led by CEO Chris Britt, the company offers fee-free checking and savings accounts, debit and credit cards, early access to direct deposits, and credit-building tools through its mobile-first platform. Deposits are FDIC-insured through partner banks including The Bancorp Bank and Stride Bank.
Revenue is generated primarily from interchange fees when members use Chime-branded cards, supplemented by lending products such as MyPay and Instant Loan and the newer Chime Invest offering. The company serves roughly 10.4 million active members, with an average revenue per active member (ARPAM) of about $260. Its competitive strengths lie in a low-cost, technology-driven operating model, a large base of mainstream and underserved consumers, and improving unit economics as it expands higher-engagement products. In digital banking, it competes with incumbent institutions and listed fintech peers such as SoFi.
The primary catalyst was the second-quarter report released in early August. Revenue of $670 million represented 27% year-over-year growth, and adjusted EBITDA of $102 million pushed the adjusted EBITDA margin to 15%, up 12 percentage points from the prior-year period. The company also recorded $28 million in GAAP net income, its second straight profitable quarter, and raised full-year revenue guidance to $2.725–$2.745 billion with adjusted EBITDA of $465–$475 million.
Product momentum reinforced the results. Chime Prime, launched in April, targets members with at least $3,000 in monthly direct deposits and has generated more than double the ARPAM of the average member. Chime Invest, introduced in July, extends the platform into self-directed and managed investing. The company also announced that Allied Universal, a large U.S. employer, signed on for the Chime Workplace suite. Supporting these moves, Chime disclosed a 10% workforce reduction aimed at efficiency, a $500 million warehouse facility with Goldman Sachs, and a CFO transition. From what I see, these updates point to improving execution.
Chime enters the back half of 2026 with raised expectations. For the third quarter, management guided to revenue of $680–$690 million and adjusted EBITDA of $105–$110 million, and it now targets roughly 1.8 million net new active members for the year, above its prior goal. The next earnings report is anticipated in November 2026.
Key factors to monitor include continued growth in active members and ARPAM, adoption of Chime Prime and Chime Invest, and the ramp of credit products such as Instant Loan and the planned revolving line of credit. Investors will also watch loss rates on lending products, the impact of the restructuring on operating leverage, and the broader health of the lower- and middle-income consumer base that Chime serves. With the stock trading at a premium multiple relative to its earnings, sustaining the profitability inflection and member-monetization trajectory will be central to the valuation debate. I’m watching this closely as the story evolves.
In my own research process, I often turn to Tickeron’s AI-driven platforms to evaluate trading strategies and compare performance across different approaches. These tools help surface systematic signals that complement traditional fundamental work, especially when assessing momentum in names like CHYM. One resource I find particularly useful is the curated selection of automated strategies that highlight top-performing bots and their track records, allowing for side-by-side evaluation of holding periods and risk metrics.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CHYM's Aroon Indicator triggered a bullish signal on September 08, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 43 similar instances where the Aroon Indicator showed a similar pattern. In of the 43 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CHYM advanced for three days, in of 61 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for CHYM moved out of overbought territory on September 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 5 similar instances where the indicator moved out of overbought territory. In of the 5 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 9 cases where CHYM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHYM as a result. In of 18 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CHYM turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 8 similar instances when the indicator turned negative. In of the 8 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHYM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CHYM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.311) is normal, around the industry mean (28.572). P/E Ratio (6.432) is within average values for comparable stocks, (76.969). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.624). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (5.435) is also within normal values, averaging (75.927).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHYM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry PackagedSoftware